Chairman's Introduction
2005-11-19 - English

Predicting the Future: The role of resistance in selecting a first-line backbone
2005-11-19 - English

The importance of the initial regimen to the overall treatment paradigm has supplied much of the impetus towards greater treatment convenience in recent years. The resultant changes in regimen composition have greatly influenced the extent and type of resistance observed at...(more)

Safeguarding the Future:Pharmacogenomics and the short and long term tolerability of abacavir/lamivudine
2005-11-19 - English

The combination of abacavir and lamivudine as a nucleoside backbone combines a favorable long-term safety and tolerability profile with limited short-term side effects, apart from abacavir hypersensitivity reactions (HSR). HSR is a well-characterized phenomenon typically...(more)

Discovering the Future: GlaxoSmithKline´s ongoing commitment to new antiretroviral development
2005-11-19 - English

GlaxoSmithKline (GSK) has maintained its leadership position in the treatment of HIV/AIDS since the introduction of Retrovir® (zidovudine, AZT), the first antiretroviral drug to be approved for the treatment of HIV infection, in April 1987. GSK currently has eight...(more)